dr. Joline Ingels (PhD)

CellGEN Therapies produces advanced gene-, cell- and tissue-therapeutic products (ATMPs) for early phase clinical trials according to good manufacturing principles (GMP).
We focus on the development and production of small batches of ATMPs or RNA vaccines as required for personalized medicines or phase I studies. In this way, we preferentially interact with academic researchers as well as companies that have developed personalized ATMPs.
We help UZ Gent, external clients and partners to move their research “from bench to bedside” by providing the right expertise, equipment and a licensed facility for the production of small batches of cell and gene therapeutics.
 

• Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. Cell Reports Medicine. 2024.
• Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials. Cytotherapy. 2022.
• Full article: Treatment of a patient with severe cytomegalovirus (CMV) infection after haploidentical stem cell transplantation with donor derived CMV specific T cells. 2021.
• T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from clinically relevant stem cell sources. Oncoimmunology, 2020. (PMID: 32117593)
• Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly. Int. J. Mol. Sci., 2020. (PMID: 32019116)
• Nanobody Based Dual Specific CARs. Int. J. Mol. Sci., 2018.( PMID: 29385713)
• An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA–loaded dendritic cells for cancer vaccination. Cytotherapy, 2018. (PMID: 30122654)
   

• Lab address: campus UZ Gent, MRB2 (entrance 38), Corneel Heymanslaan 10, 9000 Ghent